Private Equity Is Still Buying Medspas — What Your Clinic Is Worth in 2026

The era of easy money and rapid roll-ups is gone. Here's what disciplined buyers are actually paying for medspas now.

Introduction

If you own or operate a medspa, chances are you've thought about what happens next. Sell to a private equity firm? Merge with a local dermatology practice? Build a multi-location empire yourself? In 2026, those options remain on the table—but the rules of the game have changed dramatically.

The medspa M&A market didn't disappear. Private equity is still buying—actively and well-capitalized. But the land-grab phase that defined 2021–2023 is definitively over. Buyers who once chased growth at any cost are now methodical, measured, and ruthlessly focused on fundamentals. The difference isn't academic. It directly affects how much your practice is worth.

For a $1M–$3M EBITDA practice, the difference between a solid valuation and a disappointing one often comes down to three factors: your compliance track record, the reliability of your recurring revenue, and how dependent the business is on you personally. This guide will help you understand where the market stands and what you need to fix before you talk to a buyer.

The Shift From Land Grab to Disciplined M&A

For much of the post-pandemic period, medspa dealmaking looked like a gold rush. Private equity platforms and larger consolidators competed aggressively, multiples climbed, and deals closed fast. Buyers were focused on volume—acquiring as many locations as possible to build scale and demonstrate market dominance to their own investors.

That era is over.

Today's medspa M&A market operates differently. According to industry sources, "Interest in the space remains very strong," but the emphasis has shifted. "You still have the classic roll-ups, but we're also seeing new buyers enter the space and platforms recapitalize at attractive valuations"—yet the tempo of activity has slowed considerably.

The reason is straightforward: same-store performance has flat-lined. Store expansion outpaced actual market growth in many regions, and many operators discovered that adding new locations didn't necessarily improve profitability. That harsh reality forced buyers to slow down, dig deeper, and think more strategically about which practices—and which markets—are actually worth the premium multiples.

This disciplined approach is good news and bad news. Good news: if your medspa is fundamentally sound, with clean operations and solid growth, the buyers willing to move right now often have deeper pockets and longer time horizons than the early 2020s speculators. Bad news: mediocre practices that might have squeaked by in 2022 won't find a buyer at a premium multiple in 2026.

Medspa Valuation Multiples in 2026: What's Your Practice Actually Worth?

The headline number is straightforward: standalone medspas typically transact at 4x–7x EBITDA, depending on a handful of key factors. For a practice with $500,000 in annual EBITDA, that translates to a sale price of $2M–$3.5M. For $1M in EBITDA, you're looking at $4M–$7M.

That range is wide by design. The spread between the low and high end comes down to the specifics of your business.

Smaller, single-location medspas typically fall into the 3x–6x range. Higher operational risk, lower revenue diversification, and limited geographic reach all pull the multiple down. If your clinic relies heavily on one or two lead providers, or if your revenue is concentrated in a single treatment category (say, 70% injectables), buyers will discount accordingly.

Larger, established practices with proven profitability, strong brand equity, multiple revenue streams, and a broader customer base command multiples in the 7x–12x range. These operators often have multi-location footprints, centralized admin functions, and documented standard operating procedures—all signals to buyers that the business is scalable.

High-growth, tech-driven medspa brands with exceptional management, recurring revenue models, and strong retention metrics can reach 10x–20x EBITDA. These are exceptions, but they exist—and they're the outliers that attract competitive bidding and platform premiums.

The critical variable lurking beneath all these numbers is recurring revenue. Practices that derive 30–40% of revenue from membership or prepaid treatment plans can often add 0.5x–1.0x to their multiple compared to an identical practice without that recurring base. That might sound like a modest uplift, but on a $2M enterprise, it's an extra $500,000 to $1M in sale value.

Why does membership revenue matter so much? Because it's underwritable. A practice where 60–70% of revenue comes from returning, predictable clients is fundamentally less risky than one chasing new patient acquisition every month. Subscription-based models and pre-paid plans create stable cash flow, improve lifetime customer value, and reduce marketing spend relative to new-patient acquisition.

What Buyers Are Actually Looking For Now

The disciplined M&A environment of 2026 has revealed the three factors that truly drive value:

Provider Talent and Retention. Your lead injectables nurse, your laser technician, your nurse practitioner—these people are your business. If key staff members walk away during the due diligence process or immediately post-acquisition, valuation collapses. Buyers now spend significant time evaluating provider compensation, employment agreements, and non-competes. They're also offering retention bonuses and earnout structures tied to staff stability.

Operational Consistency. Buyers conduct lengthy, detailed quality-of-earnings reviews. They want to see clean financials, documented procedures, consistent patient outcomes, and real growth (not just revenue inflation). If your numbers are flat or trending down, you'll face scrutiny and discounting.

Compliance Track Record. This is the new deal-killer. In earlier phases of medspa consolidation, regulatory and compliance issues were treated as disclosure items—problems to be managed post-close. Today, they're poison. Unlicensed staff, peptides sourced from grey-market suppliers, prescriptions written by non-physicians, inadequate insurance coverage—these aren't negotiating points anymore. They're reasons for buyers to walk away or to discount multiples by 20–30%.

The Florida and Texas markets remain the hottest consolidation zones due to sheer volume and favorable business climates. But operators in these regions are also facing increased scrutiny from state boards and federal agencies. Buyers know the risk, and they're demanding clean histories.

Why Owner Independence Matters (And Why It Doesn't)

One question nearly every medspa owner asks: "Does it matter if the business depends on me?" The answer is yes—but perhaps not in the way you think.

A medspa that runs entirely on the owner-provider—the owner is the only injector, does all the consultations, manages all client relationships—will fetch a lower multiple than an identical practice with a team. That's expected. But buyers also understand that small to mid-size medspas are often founder-led and that transition takes time. What they won't pay for is a business where the owner is irreplaceable and there's no documented path to independence.

If you're a solo operator planning to sell, the buyer will likely want you to stay on for 12–24 months post-close in an advisory or transitional capacity. They'll structure your earnout to reward smooth handoff and team development. But the path to independence needs to exist in your financials and your operations before you walk into the room.

Conversely, a practice with a strong management team, documented leadership pipeline, and diversified provider revenue is worth a meaningful premium. It signals to buyers that the business can grow and sustain even without the founder, which unlocks platform economics and roll-up potential.

How to Prepare Your Medspa for a Potential Sale

If you're thinking about selling—whether in 2026 or in the next few years—start now.

Clean your compliance house. Audit your staff credentials, verify licensing, review your supplier chain (especially for injectables and other injectables), and document adherence to state regulations. If you've cut corners, fix it before a buyer discovers it in due diligence. Regulatory issues don't get cheaper when found by third parties.

Build recurring revenue. If 70% of your patients are one-time or occasional purchasers, launch a membership program. Even a modest membership tier—$199/month for unlimited consultations and a monthly micro-current facial, for example—can shift your revenue profile and unlock valuation uplift.

Document your procedures and systems. Buyers want to see proof that your practice can scale. Create an operations manual, document your clinical protocols, standardize patient intake, and build reporting dashboards. If you can't hand the business to a manager and have it run smoothly, you don't have a business worth buying at platform multiples.

Diversify revenue and patient base. Practices that rely on one treatment (injectables) or one demographic are riskier than diversified operators. Expand your service menu, build patient segments (preventative care, maintenance, specific demographics), and reduce concentration risk.

Strengthen your team. Invest in provider retention, clarify succession, and build bench strength. If your lead nurse is underpaid or your practice manager is overwhelmed, fix it now. Buyers will see it, and it will cost you millions in valuation.

GlowRoute's Role in M&A Due Diligence

Private equity teams and consolidators don't discover medspa targets by accident. They use a combination of market intelligence, industry databases, and third-party directories to identify high-performing operators in their target geographies.

Being listed on a credible directory like GlowRoute serves a dual purpose. For patients, it signals legitimacy and makes your clinic discoverable when they're searching for providers. For buyers—and their investment bankers—it signals that you're a professional operator who takes your market presence seriously. Directories are part of the due diligence process. A medspa that's missing from reputable listings, or that has sparse online presence, raises questions.

Conversely, clinics listed on quality directories with clean profiles, strong patient reviews, and documented services communicate professionalism and transparency. That communication matters more than most owners realize, particularly when buyers are evaluating 50+ potential targets and need to screen quickly.

GlowRoute makes your clinic visible and credible to the right audiences—patients, referral partners, and increasingly, M&A professionals looking for consolidation targets.

What This Means for You

If you own a medspa, you have three rough paths:

Path One: Optimize for exit. You're planning to sell in the next 2–4 years. Tighten compliance, build recurring revenue, document your systems, and strengthen your team. Get listed on quality directories. In this scenario, every dollar you invest in operations now potentially multiplies in sale value later.

Path Two: Build for scale. You want to stay in the game, expand geographically, and either sell to a larger platform later or remain independent. Same execution as Path One, but with a focus on multi-location systems, centralized staffing, and documented scalability.

Path Three: Optimize for cash flow. You're not planning to sell soon, but you want to maximize profitability and owner income. Build recurring revenue, reduce customer acquisition costs, and invest in your team. These moves improve both your day-to-day cash flow and your valuation if circumstances change.

No matter which path you choose, the fundamentals are the same: compliance, recurring revenue, operational consistency, and team strength. These are the factors that buyers scrutinize today, and they're also the drivers of a healthier, more profitable practice.

---

Is your medspa positioned for the next opportunity? Being listed on GlowRoute signals credibility to both patients and potential investors. Get listed on GlowRoute today^[1] and ensure your clinic is discoverable when it matters most.

---

Sources & Further Reading

• Medical Spa Valuation Multiples 2026 — Breakwater M&A^[2]
• Medspa Valuation Multiples Dashboard (2026 Update) — FOCUS^[3]
• MedSpa M&A Still Active, But More Disciplined — American Med Spa Association^[4]
• Selling a Medspa to Private Equity — Triumphant Partners^[5]
• Valuing Med Spas: A Comprehensive Guide — HealthFMV^[6]
• The Rise of Private Equity in the Medical Spa Industry — TNMA^[7]